Patents Assigned to Protein Potential, LLC
  • Patent number: 11324814
    Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: May 10, 2022
    Assignee: Protein Potential, LLC
    Inventors: Yun Wu, Dennis J. Kopecko, B. Kim Lee Sim, Stephen L. Hoffman
  • Publication number: 20200376107
    Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 3, 2020
    Applicant: Protein Potential, LLC
    Inventors: Yun WU, Dennis J. KOPECKO, B. Kim Lee SIM, Stephen L. HOFFMAN
  • Patent number: 10695415
    Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: June 30, 2020
    Assignee: Protein Potential, LLC
    Inventors: Yun Wu, Dennis J. Kopecko, B. Kim Lee Sim, Stephen L. Hoffman
  • Publication number: 20180264099
    Abstract: Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and/or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.
    Type: Application
    Filed: July 6, 2016
    Publication date: September 20, 2018
    Applicant: Protein Potential, LLC
    Inventors: YUN WU, Dennis J. KOPECKO, B. Kim Lee SIM, Stephen L. HOFFMAN